Last reviewed · How we verify
tumor necrosis factor inhibitors (TNFi) (tumor-necrosis-factor-inhibitors-tnfi)
tumor necrosis factor inhibitors (TNFi) (generic name: tumor-necrosis-factor-inhibitors-tnfi) is a biologic Small molecule drug developed by Pfizer. It is currently FDA-approved for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.
Tumor necrosis factor inhibitors (TNFi) are medications used to treat various conditions, including rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis, chronic nonbacterial osteomyelitis, and chronic recurrent multifocal osteomyelitis. The exact mechanism of TNFi is unknown, but they are used as interventions in clinical trials for these conditions.
At a glance
| Generic name | tumor-necrosis-factor-inhibitors-tnfi |
|---|---|
| Sponsor | Pfizer |
| Drug class | biologic |
| Target | tumor necrosis factor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Ulcerative Colitis
- Crohn's Disease
- Axial Spondyloarthritis
- Psoriatic Arthritis with Distal Interphalangeal Involvement
- Non-Radiographic Axial Spondyloarthritis
- Moderate to Severe Ulcerative Colitis
- Moderate to Severe Crohn's Disease
- Active Ankylosing Spondylitis
- Moderate to Severe Plaque Psoriasis
- Active Psoriatic Arthritis
- Active Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis with Polyarticular Course
- Juvenile Idiopathic Arthritis with Enthesitis
- Juvenile Idiopathic Arthritis with Oligoarticular Course
- Juvenile Idiopathic Arthritis with Systemic Features
Common side effects
- Injection site reaction
- Diarrhoea
- Nasopharyngitis
- Upper respiratory tract infection
- Arthralgia
- Back pain
- Urinary tract infection
- rash
- autoimmune disorder
- otitis media
- tooth infection
- urticaria
Drug interactions
- Abatacept
- Anakinra
- Azathioprine
- Cyclophosphamide
- Cyclosporine
- Etanercept
- Glatiramer acetate
- Hydroxychloroquine
- Immunosuppressants (e.g., azathioprine, cyclophosphamide, cyclosporine)
- Live vaccines
- Methotrexate
- Mycophenolate mofetil
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM) (PHASE4)
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- Lipids, Inflammation, and CV Risk in RA
- A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
- COVID-19 VaccinE Response in Rheumatology Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tumor necrosis factor inhibitors (TNFi) CI brief — competitive landscape report
- tumor necrosis factor inhibitors (TNFi) updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about tumor necrosis factor inhibitors (TNFi)
What is tumor necrosis factor inhibitors (TNFi)?
tumor necrosis factor inhibitors (TNFi) (tumor-necrosis-factor-inhibitors-tnfi) is a biologic drug developed by Pfizer, indicated for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.
What is tumor necrosis factor inhibitors (TNFi) used for?
tumor necrosis factor inhibitors (TNFi) is indicated for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Plaque Psoriasis.
Who makes tumor necrosis factor inhibitors (TNFi)?
tumor necrosis factor inhibitors (TNFi) is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What is the generic name of tumor necrosis factor inhibitors (TNFi)?
tumor-necrosis-factor-inhibitors-tnfi is the generic (nonproprietary) name of tumor necrosis factor inhibitors (TNFi).
What drug class is tumor necrosis factor inhibitors (TNFi) in?
tumor necrosis factor inhibitors (TNFi) belongs to the biologic class. See all biologic drugs at /class/biologic.
What development phase is tumor necrosis factor inhibitors (TNFi) in?
tumor necrosis factor inhibitors (TNFi) is FDA-approved (marketed).
What are the side effects of tumor necrosis factor inhibitors (TNFi)?
Common side effects of tumor necrosis factor inhibitors (TNFi) include Injection site reaction, Diarrhoea, Nasopharyngitis, Upper respiratory tract infection, Arthralgia, Back pain.
What does tumor necrosis factor inhibitors (TNFi) target?
tumor necrosis factor inhibitors (TNFi) targets tumor necrosis factor and is a biologic.
Related
- Drug class: All biologic drugs
- Target: All drugs targeting tumor necrosis factor
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Rheumatoid Arthritis
- Indication: Drugs for Psoriatic Arthritis
- Indication: Drugs for Ankylosing Spondylitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing